Condition: Multiple Myeloma · Sponsor: Arch Oncology
Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with relapsed/refractory multiple myeloma (MM).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Phoenix, Arizona, United States | — |
| Mayo Clinic | Jacksonville, Florida, United States | — |
| Emory University | Atlanta, Georgia, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| Medical College of Wisconsin and Froedtert Hospital | Milwaukee, Wisconsin, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04445701